Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO. ABRYSVO® (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular useInitial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-other
ABRYSVO is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. ABRYSVO is a vaccine indicated for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. ABRYSVO is a vaccine indicated for active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
- generic_name
- respiratory syncytial virus vaccine
- brand_name
- Sterile Water Diluent
- product_names
- Respiratory Syncytial Virus Vaccine, Sterile Water Diluent
- ndc
- 0069-0344, 0069-2465, 0069-0344-21, 0069-0344-01, 0069-0344-05, 0069-0344-10, 0069-0207, 0069-0207-01, 0069-0250, 0069-0250-01, 0069-2465-19, 0069-2465-01, 0069-2465-10
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en